B
Bullisch
Bullisch · 25%CRIS
$2.47
Szenariopreis
$0.714
+0.057 (+8.00%)Zum Schluss
Loading chart…
- Hoch
- 1.500
- Eröffnung
- 0.720
- Volumengewichteter Durchschnittskurs
- 0.94
- Volumen
- 51.14M
- Marktkap.
- 43.91M
- Tief
- 0.620
- Umsatz
- 48.31M
- EV/EBITDA, TTM
- 0.04
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
KI-Analyse of Curis Inc (CRIS)
KaufenCuris Inc appears to be a good buy right now due to its recent price surge of 75.19% over the last five days, indicating strong momentum. The RSI is at 80.385, suggesting it is in overbought territory but also reflects strong buying interest. The forward P/E ratio is currently at 0, which indicates potential for future earnings growth as the company progresses with its clinical trials. However, a significant risk is the net loss of $24.2 million reported for Q1 2026, which highlights ongoing financial challenges that could impact investor sentiment.
Analystenbewertungen (4)
+1440.83% Aufwärtspotenzial
Kaufen
4 Kaufen
0 Halten
0 Verkaufen
Aktuell: 0.71
Tief
5.00
Durchschnitt
11.00
Hoch
17.00
H.C. Wainwright
Kaufen
$43
2026-07-24
H.C. Wainwright
2026-07-24
Kursziel
$43
Kaufen
Evercore ISI
Überdurchschnittlich
$38
2026-01-05
Evercore ISI
2026-01-05
Kursziel
$38
Überdurchschnittlich
Canaccord
Halten
$30
2025-12-22
Canaccord
2025-12-22
Kursziel
$30
Halten
BofA
Kaufen
$35
2025-12-15
BofA
2025-12-15
Kursziel
$35
Kaufen
Canaccord
Halten
$28
2025-12-02
Canaccord
2025-12-02
Kursziel
$28
Halten
Bewertungskennzahlen
Das aktuelle erwartete KGV von Curis Inc (CRIS) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -1.88.
Alphio-AI-Kursszenarien für CRIS
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
9.007-30PRnewswireCuris Achieves Key Milestone in CLL Study with Emavusertib
9.007-22PRnewswireCuris Updates Clinical Data in PCNSL and Increases Guidance for CLL
2.007-06NewsfilterCuris Announces Key Enrollment Milestone in TakeAim CLL Study
8.507-06PRnewswireCuris Achieves Key Milestone in TakeAim CLL Study
- 2.006-26Newsfilter
Curis Initiates CLL Study and Confirms Shareholder Vote Results
CRIS FAQ – beantwortet von Alphio AI
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Curis Inc appears to be a good buy right now due to its recent price surge of 75.19% over the last five days, indicating strong momentum. The RSI is at 80.385, suggesting it is in overbought territory but also reflects strong buying interest. The forward P/E ratio is currently at 0, which indicates potential for future earnings growth as the company progresses with its clinical trials. However, a significant risk is the net loss of $24.2 million reported for Q1 2026, which highlights ongoing financial challenges that could impact investor sentiment.
4 analysts cover CRIS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- Stock Market Surges After 2026 Midterms: What the Democratic Sweep Means for Your PortfolioThe stock market rallied after Democrats won the 2026 midterms. Discover what the election means for investors, tech stocks, and the S&P 500 outlook.
- Stock Market Surges After 2026 Midterms: What the Democratic Sweep Means for Your PortfolioThe stock market rallied after Democrats won the 2026 midterms. Discover what the election means for investors, tech stocks, and the S&P 500 outlook.
- Oil Prices Surge Above $105 Amid US-Iran Conflict: Energy Investment Opportunities in November 2026Oil prices climb past $105 as US strikes Iran's Qeshm Island. Discover energy investment opportunities, top oil stocks, and market outlook for November 2026.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.